The United Kingdom's Microbicide Development Programme has announced the launch of a 39-month Phase III clinical trial of PRO 2000, a microbicide developed by Indevus Pharmaceuticals. The gel will be tested to determine its effects in blocking HIV and other sexually transmitted diseases among 10,000 women in Uganda, Tanzania, South Africa, and Zambia.
''''''''''
About 200 men and women in Australia and Thailand are being recruited to participate in a Phase I safety trial of VivaGel, a microbicide that aims to prevent HIV and herpes infections. Lab studies showed the compound binds to a protein on the surface of HIV, blocking it from infecting human cells.
